September 23, 2026, 10:30 AM – 12:00 PM EST
Oncology drug development has long depended on systemically administered therapies, but as the field grows more sophisticated, how and where a therapy is delivered is proving just as consequential as the therapy itself.
This live webinar brings together a distinguished panel of innovators across drug formulation, device technology, and clinical development to explore the expanding role of delivery in oncology. From the now well-established SubQ conversion pathway seen with checkpoint inhibitors and blockbuster biologics, to the scientifically compelling but underexplored case for intratumoral and loco-regional administration, the session will challenge assumptions and surface actionable insights.
Panelists will examine the dual value of delivery innovation: improving patient access and quality of life while more precisely exploiting tumor biology and the immune system to drive deeper, more durable responses.
Whether you are an early-stage biotech evaluating formulation strategy, a pharma team exploring life cycle management for an existing IV asset, or an investor tracking delivery innovation in oncology, this session offers a timely and practical forum with experts actively shaping the field.
Our panel will cover:
- The value proposition for SubQ and local alternatives to IV administration
- Benefits and strategic timing of SubQ formulation programs
- Challenges and real opportunities in intratumoral and loco-regional delivery
- Addressing industry hesitancy and funding hurdles around local delivery approaches
Panelists include:
- Charles Theuer CMO, Halozyme
- John Goldberg CMO, NanOlogy
- Matt Huddleston EVP & CCO, Enable Injections
- Stehen Hunt CMO, Vivaldi
- Laurent Levy CEO, Nanobiotix
- Marie McAvoy CSO, Nanosyrinx
- Richard Marshak CBO, TriSalus
